| Code | 4141E | ||||||||||
| MA number | 44/0180/23-S | ||||||||||
| Product Form: | tbl 90x5 mg (blis.OPA/Al/PVC/Al) | ||||||||||
| MA Status: | R - Valid Marketing Authorisation | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | Accord Healthcare Polska Sp. z o.o., Poland | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | blister OPA/Al/PVC/Al | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 04.08.2023 |
| Validity: | 04.08.2028 |
| SPC: |
SPC_Everolimus Accord_07 2023.pdf
|
| PIL: |
PIL_Everolimus Accord_07 2023.pdf
|
| Safety feature | Yes |
| Data update: | 16.08.2023 |
